文献速递肝病

巴氯芬与阿坎酸治疗代偿性酒精性肝硬化的主要肝脏不良结局比较

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol-Associated Cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2026-03-17

这项全国多中心队列研究采用目标试验模拟框架,比较巴氯芬与阿坎酸在代偿性酒精性肝硬化患者中的安全性。倾向评分匹配后各571例,巴氯芬组1年MALO发生率为34.3%,高于阿坎酸组的27.4%(HR 1.32,95%CI 1.02-1.70),肝性脑病风险亦更高(HR 1.80,95%CI 1.21-2.69)。

要点

  • 代偿性酒精性肝硬化患者中,巴氯芬较阿坎酸增加1年主要肝脏不良结局风险。
  • 巴氯芬与肝性脑病风险升高相关,其他单个失代偿事件及死亡率无显著差异。
  • 56-70岁患者亚组分析提示巴氯芬风险可能更高。

核心结论

  • 在代偿性酒精性肝硬化患者中,巴氯芬较阿坎酸与更高的肝性脑病风险相关。

研究设计与样本

  • 全国多中心队列研究,采用目标试验模拟框架,纳入确诊6个月内首次处方巴氯芬或阿坎酸的代偿性酒精性肝硬化成人。
  • 采用1:1倾向评分匹配平衡60个协变量,匹配后巴氯芬组和阿坎酸组各571例。

主要发现

  • 巴氯芬组1年MALO发生率为34.3%,阿坎酸组为27.4%,HR为1.32(95%CI 1.02-1.70)。
  • 巴氯芬与肝性脑病风险升高相关(HR 1.80;95%CI 1.21-2.69)。
  • 其他单个失代偿事件及死亡率无显著差异。
  • 亚组分析提示56-70岁患者中巴氯芬风险更高。

关键数值与推荐

  • 主要结局MALO定义为12个月内肝失代偿事件的复合终点。
  • 巴氯芬组1年MALO发生率34.3%,阿坎酸组27.4%,HR 1.32(95%CI 1.02-1.70)。
  • 肝性脑病HR 1.80(95%CI 1.21-2.69)。

临床怎么用

  • 在代偿性酒精性肝硬化患者中选择酒精使用障碍药物治疗时,需权衡巴氯芬相关肝性脑病风险。
  • 对56-70岁患者处方巴氯芬时应加强肝性脑病监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acamprosate is generally considered safe in patients with liver disease because it is renally cleared. Baclofen has been shown to be safe and effective in patients with alcohol use disorder and alcohol-associated cirrhosis. Both medications are guideline-endorsed pharmacotherapies for patients with alcohol-associated cirrhosis. However, the safety of baclofen relative to acamprosate remains uncertain. AIMS: To compare the safety profiles of baclofen and acamprosate in patients with alcohol-associated cirrhosis. METHODS: We conducted a nationwide, multicenter cohort study using a target trial emulation framework. Adults with compensated alcohol-associated cirrhosis who received a first prescription of baclofen or acamprosate within 6 months of diagnosis were included. Propensity score matching (1:1) was used to balance 60 covariates. The primary outcome was major adverse liver outcomes (MALO), defined as a composite of hepatic decompensation events within 12 months. Secondary outcomes included individual decompensation events and mortality. RESULTS: After matching, 571 baclofen and 571 acamprosate initiators were analysed. The 1-year incidence of MALO was higher in the baclofen group (34.3%) than in the acamprosate group (27.4%), corresponding to a hazard ratio (HR) of 1.32 (95% CI, 1.02-1.70). Among individual events, baclofen was associated with a higher risk of hepatic encephalopathy (HR 1.80; 95% CI, 1.21-2.69). No significant differences in other individual events or mortality were observed. Subgroup analyses suggested greater risk among patients aged 56-70 years. CONCLUSIONS: In this large real-world study, baclofen was associated with a higher risk of hepatic encephalopathy compared with acamprosate in patients with compensated alcohol-associated cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yeo YH, Mehravar S, Choi E, et al. Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol-Associated Cirrhosis. Aliment Pharmacol Ther. 2026. PMID: 41842890. doi:10.1111/apt.70619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。